JOHN L HIGGINS Insider Trading $LGND LIGAND PHARMACEUTICALS INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN L HIGGINS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN L HIGGINS. JOHN L HIGGINS is Chief Executive Officer in LIGAND PHARMACEUTICALS INC ($LGND) and in BIO-TECHNE Corp ($TECH) and Director in BIO-TECHNE Corp ($TECH) and EVP, Finance, Corp Dev. & CFO in CONNETICS CORP ($CNCT).
JOHN L HIGGINS in LIGAND PHARMACEUTICALS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of JOHN L HIGGINS: Chief Executive Officer
Holdings: 340,696 shares
Current Value: $36,740,657
Latest Transaction: Feb 09 2021
$LGND Market Capitalization: $2.24B
$LGND Previous Close: $107.84
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of JOHN L HIGGINS in LIGAND PHARMACEUTICALS INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, TECH, CNCT, LGND
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 54,666 | 791,017 | 14,334 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 10.05 | 60,000 | 603,000 | 0 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 203.03 | 2,970 | 602,999 | 343,060 | 346 K to 343.1 K (-0.86 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 10.05 | 60,000 | 603,000 | 346,030 | 286 K to 346 K (+20.98 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 203.40 | 54,666 | 11,119,239 | 286,030 | 340.7 K to 286 K (-16.05 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 54,666 | 791,017 | 340,696 | 286 K to 340.7 K (+19.11 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 177.50 | 25,113 | 4,457,558 | 25,113 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 12,608 | 0 | 286,030 | 273.4 K to 286 K (+4.61 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.92 | 30,000 | 657,600 | 65,616 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 40,000 | 578,800 | 69,000 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 50,000 | 723,500 | 109,000 | |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.92 | 30,000 | 657,600 | 273,422 | 243.4 K to 273.4 K (+12.32 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 182.00 | 40,000 | 7,280,000 | 243,422 | 283.4 K to 243.4 K (-14.11 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 40,000 | 578,800 | 283,422 | 243.4 K to 283.4 K (+16.43 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 156.01 | 4,596 | 717,022 | 243,422 | 248 K to 243.4 K (-1.85 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 9,607 | 0 | 248,018 | 238.4 K to 248 K (+4.03 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 156.01 | 2,845 | 443,848 | 238,411 | 241.3 K to 238.4 K (-1.18 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 5,946 | 0 | 241,256 | 235.3 K to 241.3 K (+2.53 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 159.00 | 50,000 | 7,950,000 | 235,310 | 285.3 K to 235.3 K (-17.52 %) |
| Jan 27 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 50,000 | 723,500 | 285,310 | 235.3 K to 285.3 K (+21.25 %) |
| Jan 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | J | 84.53 | 223 | 18,851 | 235,310 | 235.1 K to 235.3 K (+0.09 %) |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 85.79 | 1,165 | 99,945 | 54,226 | |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 74.42 | 1,373 | 102,179 | 93,627 | |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 56.26 | 1,777 | 99,974 | 54,421 | |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 74.42 | 1,373 | 102,179 | 204,571 | 203.2 K to 204.6 K (+0.68 %) |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 56.26 | 1,777 | 99,974 | 203,198 | 201.4 K to 203.2 K (+0.88 %) |
| Jul 09 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 85.79 | 1,165 | 99,945 | 201,421 | 200.3 K to 201.4 K (+0.58 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 120.86 | 1,310 | 158,327 | 133,982 | 135.3 K to 134 K (-0.97 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 120.86 | 1,689 | 204,133 | 135,292 | 137 K to 135.3 K (-1.23 %) |
| Apr 24 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 120.86 | 1,918 | 231,809 | 136,981 | 138.9 K to 137 K (-1.38 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 9.96 | 48,125 | 479,325 | 0 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 95.68 | 60,886 | 5,825,572 | 60,886 | |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 97.23 | 2,117 | 205,836 | 205,173 | 207.3 K to 205.2 K (-1.02 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 97.23 | 1,310 | 127,371 | 207,290 | 208.6 K to 207.3 K (-0.63 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 97.23 | 1,689 | 164,221 | 208,600 | 210.3 K to 208.6 K (-0.80 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 13,559 | 0 | 210,289 | 196.7 K to 210.3 K (+6.89 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 95.68 | 5,009 | 479,261 | 196,730 | 201.7 K to 196.7 K (-2.48 %) |
| Feb 18 2020 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 9.96 | 48,125 | 479,325 | 201,739 | 153.6 K to 201.7 K (+31.33 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 105.87 | 2,948 | 312,105 | 153,614 | 156.6 K to 153.6 K (-1.88 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 5,946 | 0 | 156,562 | 150.6 K to 156.6 K (+3.95 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 105.87 | 3,801 | 402,412 | 150,616 | 154.4 K to 150.6 K (-2.46 %) |
| Dec 26 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 7,668 | 0 | 154,417 | 146.7 K to 154.4 K (+5.23 %) |
| Jul 31 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | P | 95.45 | 1,850 | 176,583 | 146,749 | 144.9 K to 146.7 K (+1.28 %) |
| May 31 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | P | 108.20 | 1,000 | 108,202 | 144,899 | 143.9 K to 144.9 K (+0.69 %) |
| May 31 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | P | 108.20 | 1,000 | 108,202 | 144,899 | 143.9 K to 144.9 K (+0.69 %) |
| May 14 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | P | 113.50 | 2,500 | 283,750 | 143,899 | 141.4 K to 143.9 K (+1.77 %) |
| Mar 15 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | P | 114.29 | 2,500 | 285,725 | 141,399 | 138.9 K to 141.4 K (+1.80 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 111.78 | 3,168 | 354,119 | 126,090 | 129.3 K to 126.1 K (-2.45 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 6,390 | 0 | 129,258 | 122.9 K to 129.3 K (+5.20 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 111.78 | 3,597 | 402,073 | 122,868 | 126.5 K to 122.9 K (-2.84 %) |
| Jan 25 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 7,256 | 0 | 126,465 | 119.2 K to 126.5 K (+6.09 %) |
| Jan 14 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 16.14 | 4,000 | 64,560 | 0 | |
| Jan 14 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 16.14 | 29,790 | 480,811 | 0 | |
| Jan 14 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 16.14 | 29,790 | 480,811 | 119,209 | 89.4 K to 119.2 K (+33.32 %) |
| Jan 14 2019 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 16.14 | 4,000 | 64,560 | 89,419 | 85.4 K to 89.4 K (+4.68 %) |
| Aug 31 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 258.25 | 3,500 | 903,875 | 85,419 | 88.9 K to 85.4 K (-3.94 %) |
| Aug 17 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 12,993 | 188,009 | 159,000 | |
| Aug 17 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 3,007 | 43,511 | 171,993 | |
| Aug 17 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 243.00 | 12,993 | 3,157,299 | 88,919 | 101.9 K to 88.9 K (-12.75 %) |
| Aug 17 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 12,993 | 188,009 | 101,912 | 88.9 K to 101.9 K (+14.61 %) |
| Aug 17 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 241.33 | 21,507 | 5,190,261 | 88,919 | 110.4 K to 88.9 K (-19.48 %) |
| Aug 17 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 3,007 | 43,511 | 110,426 | 107.4 K to 110.4 K (+2.80 %) |
| May 15 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 16.14 | 12,405 | 200,217 | 29,790 | |
| May 15 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 179.97 | 12,405 | 2,232,491 | 107,419 | 119.8 K to 107.4 K (-10.35 %) |
| May 15 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 16.14 | 12,405 | 200,217 | 119,824 | 107.4 K to 119.8 K (+11.55 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 159.01 | 41,392 | 6,581,742 | 41,392 | |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 165.87 | 2,982 | 494,624 | 107,419 | 110.4 K to 107.4 K (-2.70 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 6,015 | 0 | 110,401 | 104.4 K to 110.4 K (+5.76 %) |
| Mar 06 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 7,928 | 0 | 104,386 | 96.5 K to 104.4 K (+8.22 %) |
| Feb 16 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 157.18 | 1,689 | 265,477 | 96,458 | 98.1 K to 96.5 K (-1.72 %) |
| Feb 16 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 157.18 | 1,918 | 301,471 | 98,147 | 100.1 K to 98.1 K (-1.92 %) |
| Feb 16 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 157.18 | 2,635 | 414,169 | 100,065 | 102.7 K to 100.1 K (-2.57 %) |
| Feb 16 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 157.03 | 9,000 | 1,413,279 | 102,700 | 111.7 K to 102.7 K (-8.06 %) |
| Jan 26 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 165.00 | 22,500 | 3,712,500 | 111,700 | 134.2 K to 111.7 K (-16.77 %) |
| Jan 22 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 16.14 | 16,249 | 262,259 | 42,195 | |
| Jan 22 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 151.93 | 11,850 | 1,800,307 | 134,200 | 146.1 K to 134.2 K (-8.11 %) |
| Jan 22 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 155.00 | 16,249 | 2,518,595 | 146,050 | 162.3 K to 146.1 K (-10.01 %) |
| Jan 22 2018 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 16.14 | 16,249 | 262,259 | 162,299 | 146.1 K to 162.3 K (+11.13 %) |
| Dec 29 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 138.66 | 5,199 | 720,893 | 146,050 | 151.2 K to 146.1 K (-3.44 %) |
| Dec 29 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 9,965 | 0 | 151,249 | 141.3 K to 151.2 K (+7.05 %) |
| Nov 20 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 140.34 | 2,258 | 316,888 | 141,284 | 143.5 K to 141.3 K (-1.57 %) |
| Nov 17 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 142.53 | 5,269 | 750,991 | 143,542 | 148.8 K to 143.5 K (-3.54 %) |
| Oct 17 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.92 | 11,384 | 249,537 | 0 | |
| Oct 17 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 143.04 | 1,744 | 249,462 | 148,811 | 150.6 K to 148.8 K (-1.16 %) |
| Oct 17 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.92 | 11,384 | 249,537 | 150,555 | 139.2 K to 150.6 K (+8.18 %) |
| Sep 06 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.00 | 5,000 | 105,000 | 0 | |
| Sep 06 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 130.00 | 5,000 | 650,000 | 139,171 | 144.2 K to 139.2 K (-3.47 %) |
| Sep 06 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.00 | 5,000 | 105,000 | 144,171 | 139.2 K to 144.2 K (+3.59 %) |
| Aug 10 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.00 | 5,483 | 115,143 | 5,000 | |
| Aug 10 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 125.00 | 5,483 | 685,375 | 139,171 | 144.7 K to 139.2 K (-3.79 %) |
| Aug 10 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.00 | 5,483 | 115,143 | 144,654 | 139.2 K to 144.7 K (+3.94 %) |
| Jun 23 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.00 | 4,666 | 97,986 | 0 | |
| Jun 23 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 21.00 | 4,666 | 97,986 | 4,666 | |
| Jun 23 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 120.00 | 4,666 | 559,920 | 139,171 | 143.8 K to 139.2 K (-3.24 %) |
| Jun 23 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.00 | 4,666 | 97,986 | 143,837 | 139.2 K to 143.8 K (+3.35 %) |
| Jun 09 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.00 | 12,000 | 252,000 | 10,483 | |
| Jun 09 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 114.87 | 12,000 | 1,378,440 | 139,171 | 151.2 K to 139.2 K (-7.94 %) |
| Jun 09 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.00 | 12,000 | 252,000 | 151,171 | 139.2 K to 151.2 K (+8.62 %) |
| Mar 21 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 109.10 | 4,000 | 436,400 | 139,171 | 143.2 K to 139.2 K (-2.79 %) |
| Mar 10 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 10.05 | 15,675 | 157,534 | 0 | |
| Mar 10 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 106.92 | 1,473 | 157,493 | 143,171 | 144.6 K to 143.2 K (-1.02 %) |
| Mar 10 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 10.05 | 15,675 | 157,534 | 144,644 | 129 K to 144.6 K (+12.15 %) |
| Mar 10 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 107.06 | 4,000 | 428,240 | 128,969 | 133 K to 129 K (-3.01 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 100.38 | 43,646 | 4,381,185 | 43,646 | |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 10,224 | 0 | 132,969 | 122.7 K to 133 K (+8.33 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 100.38 | 4,783 | 480,118 | 122,745 | 127.5 K to 122.7 K (-3.75 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 9,168 | 0 | 127,528 | 118.4 K to 127.5 K (+7.75 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 104.28 | 2,019 | 210,541 | 118,360 | 120.4 K to 118.4 K (-1.68 %) |
| Feb 28 2017 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 104.28 | 2,285 | 238,280 | 120,379 | 122.7 K to 120.4 K (-1.86 %) |
| Sep 23 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 117.34 | 3,000 | 352,020 | 122,664 | 125.7 K to 122.7 K (-2.39 %) |
| Mar 09 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 21.00 | 6,000 | 126,000 | 22,483 | |
| Mar 09 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 21.00 | 6,000 | 126,000 | 125,664 | 119.7 K to 125.7 K (+5.01 %) |
| Mar 09 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 102.97 | 556 | 57,251 | 119,664 | 120.2 K to 119.7 K (-0.46 %) |
| Mar 09 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 102.44 | 10,277 | 1,052,776 | 120,220 | 130.5 K to 120.2 K (-7.88 %) |
| Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 85.79 | 55,391 | 4,751,994 | 55,391 | |
| Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 85.97 | 2,492 | 214,237 | 130,497 | 133 K to 130.5 K (-1.87 %) |
| Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 11,611 | 0 | 132,989 | 121.4 K to 133 K (+9.57 %) |
| Aug 07 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 110.79 | 4,666 | 516,946 | 121,378 | 126 K to 121.4 K (-3.70 %) |
| Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 95.06 | 500 | 47,530 | 126,044 | 126.5 K to 126 K (-0.40 %) |
| Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 93.21 | 3,300 | 307,593 | 126,544 | 129.8 K to 126.5 K (-2.54 %) |
| Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 92.53 | 6,200 | 573,686 | 129,844 | 136 K to 129.8 K (-4.56 %) |
Page: 1